Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing ...

A calculated flaw in perfection. New research suggests that Renaissance master artist Michelangelo Buonarroti had etched a ...

SKOPJE – A bottleneck in health-care services is causing dangerous delays in the diagnosis and treatment of breast cancer in ...

Yale study reveals cultural influences in breast cancer surgery decisions, focusing on challenges faced by women of color post-mastectomy.

Breast cancer rates rose by 1 percent per year from 2012-2021 for all U.S. women combined, with steeper increases for women under 50 and Asian American and Pacific Islander women, according to the ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing ...

Ahead of the Bengals-Giants game on Sunday, Oct. 13, Jill joined the program to discuss her history with breast cancer and urge viewers to consider genetic testing if they're high risk — a step ...

More than $500,000 was expected to be raised for the American Cancer Society. The walk is a celebration of courage and hope and a movement that unites communities to end breast cancer, according ...

Over the summer, the researchers published a new study in the journal Nutrients showing that Manuka honey could have the ...